Form 4: LifeCore Biomedical CEO Paul Josephs Acquires Shares, Disposes of Some for Tax Obligations

LifeCore Biomedical's CEO, Paul Josephs, acquired 38,461 shares and disposed of 11,769 shares to cover tax obligations on December 6, 2024.

Summary

• On December 6, 2024, Paul Josephs, the CEO of LifeCore Biomedical, acquired 38,461 shares of common stock.
• On the same day, Mr. Josephs disposed of 11,769 shares of common stock at a price of $7.15 per share.
• The disposal of shares was to satisfy tax withholding obligations related to the stock grant.
• Following these transactions, Mr. Josephs beneficially owns 542,717 shares of LifeCore Biomedical common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions and does not indicate any significant positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for executives who receive stock-based compensation and need to cover tax obligations.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.

Key Dates

Keywords

LifeCore Biomedical, LFCR, Paul Josephs, stock acquisition, stock disposal, insider trading, Form 4, tax obligations, CEO